NEUROCRINE BIOSCIENCES INC
For the period ended Jun 30, 2024. Filed Aug 1, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 1, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The following exhibits are filed as part of, or incorporated by reference into, this report:
| Exhibit | ||
|---|---|---|
| 3.1 | Description: | Certificate of Incorporation, as amended |
| Reference: | Incorporated by reference to Exhibit 3.1 of the Company’s Quarterly Report on Form 10-Q filed on November 5, 2018 | |
| 3.2 | Description: | Bylaws, as amended |
| Reference: | Incorporated by reference to Exhibit 3.2 of the Company’s Quarterly Report on Form 10-Q filed on August 1, 2023 | |
| 3.3 | Description: | Certificate of Amendment of Bylaws |
| Reference: | Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed on May 28, 2024 | |
| 4.1 | Description: | Form of Common Stock Certificate |
| Reference: | Incorporated by reference to the Company’s Registration Statement on Form S-1 (Registration No. 333-03172) | |
| 4.2 | Description: | Indenture, dated as of May 2, 2017, by and between the Company and U.S. Bank National Association, as Trustee |
| Reference: | Incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed on May 2, 2017 | |
| 4.3 | Description: | First Supplemental Indenture, dated as of December 22, 2021, by and between the Company and U.S. Bank National Association, as Trustee |
| Reference: | Incorporated by reference to Exhibit 4.3 of the Company’s Annual Report on Form 10-K filed on February 11, 2022 | |
| 4.4 | Description: | Form of Note representing the Company’s 2.25% Convertible Notes due 2024 |
| Reference: | Incorporated by reference to Exhibit 99.1 of the Company’s Current Report on Form 8-K filed on May 2, 2017 | |
| 10.1+ | Description: | Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan, as amended and restated |
| 10.2* | Description: | First Amendment to the Collaboration and License Agreement, effective April 3, 2024, between the Company and Voyager Therapeutics, Inc. |
| 31.1 | Description: | Certification of Chief Executive Officer pursuant to Rules 13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934 |
| 31.2 | Description: | Certification of Chief Financial Officer pursuant to Rules 13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934 |
| 32** | Description: | Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 101.INS | Description: | Inline XBRL Instance Document. – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH | Description: | Inline XBRL Taxonomy Extension Schema Document. |
| 101.CAL | Description: | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF | Description: | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB | Description: | Inline XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE | Description: | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104 | Description: | Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibit 101) |
- Management contract or compensatory arrangement.
- Certain information in this exhibit has been omitted pursuant to Item 601 of Regulation S-K.
** These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of Neurocrine Biosciences, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Except as specifically noted above, the Company’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K have a Commission File Number of 000-22705.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.